Arthur M. Cohen & Associates LLC Has $294,000 Holdings in DexCom, Inc. (NASDAQ:DXCM)

Arthur M. Cohen & Associates LLC cut its position in DexCom, Inc. (NASDAQ:DXCM) by 57.5% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 4,458 shares of the medical device company’s stock after selling 6,020 shares during the quarter. Arthur M. Cohen & Associates LLC’s holdings in DexCom were worth $294,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of the company. Crewe Advisors LLC acquired a new stake in DexCom in the 1st quarter worth $29,000. Migdal Insurance & Financial Holdings Ltd. acquired a new stake in DexCom in the 2nd quarter worth $25,000. Sachetta LLC grew its position in DexCom by 255.2% in the 2nd quarter. Sachetta LLC now owns 238 shares of the medical device company’s stock worth $27,000 after purchasing an additional 171 shares during the last quarter. DT Investment Partners LLC grew its position in DexCom by 492.2% in the 2nd quarter. DT Investment Partners LLC now owns 379 shares of the medical device company’s stock worth $43,000 after purchasing an additional 315 shares during the last quarter. Finally, Riverview Trust Co grew its position in DexCom by 100.4% in the 3rd quarter. Riverview Trust Co now owns 463 shares of the medical device company’s stock worth $31,000 after purchasing an additional 232 shares during the last quarter. 97.75% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at DexCom

In other DexCom news, COO Jacob Steven Leach sold 746 shares of the company’s stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $69.15, for a total value of $51,585.90. Following the completion of the sale, the chief operating officer now owns 264,915 shares of the company’s stock, valued at $18,318,872.25. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In other DexCom news, EVP Sadie Stern sold 426 shares of the firm’s stock in a transaction on Monday, September 9th. The stock was sold at an average price of $69.15, for a total transaction of $29,457.90. Following the completion of the transaction, the executive vice president now owns 75,451 shares of the company’s stock, valued at approximately $5,217,436.65. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, COO Jacob Steven Leach sold 746 shares of the firm’s stock in a transaction on Monday, September 9th. The shares were sold at an average price of $69.15, for a total value of $51,585.90. Following the transaction, the chief operating officer now owns 264,915 shares of the company’s stock, valued at $18,318,872.25. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 0.30% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on the stock. Leerink Partners decreased their target price on shares of DexCom from $90.00 to $87.00 and set an “outperform” rating on the stock in a research report on Friday, October 25th. Robert W. Baird boosted their target price on shares of DexCom from $80.00 to $82.00 and gave the stock a “neutral” rating in a research note on Monday, August 5th. BTIG Research lowered their price target on shares of DexCom from $156.00 to $120.00 and set a “buy” rating for the company in a research report on Friday, July 26th. Piper Sandler reiterated an “overweight” rating and set a $90.00 price target on shares of DexCom in a research report on Monday, August 26th. Finally, Baird R W cut shares of DexCom from a “strong-buy” rating to a “hold” rating in a report on Friday, July 26th. Seven analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $104.59.

DexCom Stock Performance

DexCom stock traded down $0.50 during midday trading on Tuesday, reaching $69.20. The stock had a trading volume of 62,170 shares, compared to its average volume of 3,885,632. DexCom, Inc. has a 12 month low of $62.34 and a 12 month high of $142.00. The firm’s 50-day moving average price is $69.77 and its 200 day moving average price is $94.92. The firm has a market capitalization of $27.03 billion, a PE ratio of 41.74, a P/E/G ratio of 2.16 and a beta of 1.17. The company has a quick ratio of 2.12, a current ratio of 2.46 and a debt-to-equity ratio of 1.23.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.